share_log

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45

Evercore ISI集团维持对avidity biosciences的优异表现评级,并将目标股价上调至45美元。
Benzinga ·  06/12 13:52

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $40 to $45.

Evercore ISI集团分析师Josh Schimmer认为Avidity Biosciences(纳斯达克:RNA)具有超强表现,并将目标价格从40美元上调至45美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发